Is This Fast-Growing Supplement Stock the Market’s Best-Kept Secret?

While the word health might lead most of us to think of a doctor’s appointment, nutritional supplements have become an increasingly popular way to fix deficiencies in diet or simply give your organism a little added boost. LifeVantage (NASDAQ: LFVN) is a provider of such supplements and operates on a direct-to-consumer (D2C) sales model.

So, why should you focus on LFVN stock in particular and not that of some peer or rival? Well, for one, it has gone up by 127.87% in value compared to this time last year. 

However, impressive as that was, we’re all keenly aware that past performance is not indicative of future results. But here’s something more forward-looking — let’s turn to our proprietary quant rating system.

LifeVantage stock has an overall Zen Rating of A, which places it in the top 5% of the more than 4,600 equities our system tracks. Stocks of this caliber have provided an average annual return of 32.52% since the early 2000s.

Each Zen Rating takes into account 115 proprietary factors that correlate with outsized returns, which are separated into 7 Component Grade ratings. Most stocks, even those with a Zen Rating of A, have a single Component Grade that is rated A.

LFVN, however, has three. What’s even more impressive are the exact rankings. In terms of Value, Growth, and Financials, the stock ranks in the top 2%, 2%, and 1%, respectively, of the more than 4,600 equities that our system tracks.

At a price-to-earnings (P/E) ratio of 26.22x, LFVN is noticeably affordable when compared to the wider market average of 30.39x. When it comes to the balance sheet, margins have expanded from 1.4% to 3.5% over the last year, while the company’s short-term assets ($45.79 million) exceed the combined worth of its short-term liabilities ($27.55 million) and long-term liabilities ($11.09 million).

In addition, the company’s last earnings call saw a 120% year-over-year (YoY) increase in earnings, which, at $0.22, came in significantly above the $0.13 consensus estimate

There’s also an auspicious bullish catalyst at play. The company recently expanded into key markets in Asia — the Philippines, Taiwan, Hong Kong, and Singapore. 

With the addition of a revamped D2C business model and promising results from the company’s MindBody GLP-1 System, there are plenty of reasons to be bullish — particularly as LifeVantage’s expansion into Canada, Mexico, and Europe in February 2025 went rather smoothly.

LFVN has gone relatively unnoticed thus far — only two analysts cover the stock, which currently has one Strong Buy rating and one Buy rating. The analysts initiated coverage in late December and early January. At present, their 12-month price forecasts imply an average upside of 93.9%.

Readers interested in this small-cap supplement company should mark May 1st on their calendars — that’s when the business will hold its Q3 2025 earnings call, which should provide a better overview of LifeVantage’s trajectory. 

—> Click here to research LFVN. If you like what you saw here, you also might want to take a gander at our Best Growth Stocks to Buy Now screener.

What to Do Next?

• 8 Stock Lists You Need Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return > 
• 4 Step Process to Find More 100%+ Stock Winners >

Want to get in touch? Email us at news@wallstreetzen.com.